November 25th 2025, 10:00pm
By Ryan Scott
Stage 1 polycythemia vera is manageable with monitoring, phlebotomy, medication and lifestyle changes, allowing patients to live healthy, normal lives.
November 25th 2025, 9:00pm
By Alex Biese
Immunotherapies have represented a revolution in the landscape of cancer treatment — and may have a crucial partner in the form of personalized cancer vaccines.
November 25th 2025, 7:32pm
The FDA approved Imfinzi with chemotherapy for adults with resectable gastric or gastroesophageal junction adenocarcinoma.
November 25th 2025, 6:00pm
By Bonnie Annis
Surviving breast cancer changes the way you see your body. Every ache, every spot, every unfamiliar sensation becomes a quiet question: “Could it be coming back?”
November 25th 2025, 5:00pm
From diagnosis to treatment, here is what patients need to know about squamous cell carcinoma of the bladder.
November 25th 2025, 4:00pm
The FDA granted fast track designation to AVZO-103 for the treatment of patients with previously treated locally advanced or metastatic urothelial cancer.
November 25th 2025, 2:00pm
By Spencer Feldman
An expert explains how minimally invasive surgery helps remove smaller lung areas with quicker recovery and improves outcomes for patients with early-stage lung cancer.
November 24th 2025, 10:00pm
By Georgia Hurst
I share how the holidays feel different after loss and how grief, love and gratitude can coexist as I navigate this season with gentleness and care.
November 24th 2025, 9:00pm
Dr. Charles M. Rudin highlights T cell engagers, antibody-drug conjugates and emerging strategies showing early benefits for small cell lung cancer.
November 24th 2025, 8:00pm
The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients with polycythemia vera.
November 24th 2025, 5:58pm
Voranigo was safe and well tolerated in patients with grade 3 or 4 IDH-mutant gliomas, a type of brain cancer.
November 24th 2025, 5:00pm
Sac-TMT plus Keytruda improved time without cancer growth in people with advanced lung cancer whose tumors show programmed death ligand 1.
November 24th 2025, 4:05pm
By Ashling Wahner
Imbruvica plus R-MPV led to high response rates and was tolerable for patients with newly diagnosed primary central nervous system lymphoma.
November 24th 2025, 2:00pm
By Dr. Pamela L. Kunz
Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.
November 24th 2025, 1:12pm
By Samantha Shenoy, MSN, NP
Panelists discuss how healthcare providers and patients should understand that talquetamab's unique side effects are temporary and resolve over time even while continuing treatment, emphasizing the drug's excellent efficacy and the importance of removing stigma around its manageable toxicity profile.
Understanding Stage 1 Polycythemia Vera: What Every Patient Should Know
How Vaccines Can Partner With Immunotherapy to Treat Lung Cancer
FDA Approves Imfinzi Plus Chemo in GC/GEJC
More Than a Cyst: The Fear Cancer Leaves Behind